Vireo Growth (VREOF) Non-Current Assets (2020 - 2026)

Vireo Growth (VREOF) reported Non-Current Assets of $670.5 million for Q1 2026, up 1279.27% on a YoY basis from $48.6 million in Q1 2025, and up 30.93% sequentially from $512.1 million in Q4 2025.

Vireo Growth (VREOF) Non-Current Assets (2020 - 2026) Analysis & Trends

Vireo Growth (VREOF) has 7 years of Non-Current Assets data on file, last reported at $670.5 million in Q1 2026.

  • For the quarter ending Q1 2026, Non-Current Assets rose 1279.27% year-over-year to $670.5 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 billion (up 884.23% YoY), and the FY2025 full-year result was $512.1 million, up 956.06% from the prior year.
  • Non-Current Assets improved to $670.5 million in Q1 2026, from $512.1 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $670.5 million in Q1 2026 to a low of $34.4 million in Q4 2023.
  • A 5-year average of $162.8 million and a median of $49.9 million in 2024 frame the typical range for Non-Current Assets.
  • Across the five-year window, Non-Current Assets sank 69.4% in 2023 and soared 1279.27% in 2026, its largest moves.
  • Tracing VREOF's Non-Current Assets over 5 years: stood at $112.4 million in 2022, then slumped by 69.39% to $34.4 million in 2023, then surged by 40.92% to $48.5 million in 2024, then surged by 956.06% to $512.1 million in 2025, then jumped by 30.93% to $670.5 million in 2026.
  • Business Quant data shows VREOF's Non-Current Assets at $670.5 million in Q1 2026, $512.1 million in Q4 2025, and $371.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 36.78 Bn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 26.33 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 8.68 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 79.20 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 3.84 Bn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - 15.70 Bn
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 25.92 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 2.47 Bn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 9.64 Bn
10 Vireo Growth 10.57 Bn 10.41 Bn 59.30 Mn 670.50 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 670.50 Mn
Dec 31, 2025 512.10 Mn
Sep 30, 2025 370.95 Mn
Jun 30, 2025 346.55 Mn
Mar 31, 2025 48.61 Mn
Dec 31, 2024 48.49 Mn
Sep 30, 2024 49.90 Mn
Jun 30, 2024 46.05 Mn
Mar 31, 2024 43.71 Mn
Dec 31, 2023 34.41 Mn
Sep 30, 2023 36.56 Mn
Jun 30, 2023 39.58 Mn
Mar 31, 2023 43.08 Mn
Dec 31, 2022 112.43 Mn
Sep 30, 2022 119.46 Mn
Jun 30, 2022 122.43 Mn
Mar 31, 2022 121.98 Mn
Dec 31, 2021 125.33 Mn
Sep 30, 2021 119.41 Mn
Jun 30, 2021 70.71 Mn